Published in Proc Natl Acad Sci U S A on September 20, 2004
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity (2009) 4.69
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res (2009) 3.83
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother (2009) 3.11
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A (2008) 2.20
High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther (2005) 2.04
Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol (2010) 1.94
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer (2014) 1.92
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol (2010) 1.84
Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Curr Opin Immunol (2005) 1.74
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant (2010) 1.72
Toll-like receptors in tumor immunotherapy. Clin Cancer Res (2007) 1.60
Therapy for metastatic melanoma: the past, present, and future. BMC Med (2012) 1.57
Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol (2008) 1.44
Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res (2005) 1.36
Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res (2010) 1.27
Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J (2012) 1.26
A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc Natl Acad Sci U S A (2005) 1.25
Functions of γC cytokines in immune homeostasis: current and potential clinical applications. Clin Immunol (2009) 1.22
Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res (2009) 1.15
In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer. J Transl Med (2006) 1.15
Cancer immunotherapy. Mol Oncol (2012) 1.13
Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett (2008) 1.13
Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: differing impact on CD8 T cell phenotype and responsiveness to restimulation. J Transl Med (2010) 1.12
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin Oncol (2015) 1.06
Engineering T cells for cancer therapy. Br J Cancer (2005) 1.05
Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics (2008) 1.03
Exploiting T cell receptor genes for cancer immunotherapy. Clin Exp Immunol (2005) 1.01
T-cell immunotherapy: looking forward. Mol Ther (2014) 1.00
Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica (2009) 1.00
Cord blood in regenerative medicine: do we need immune suppression? J Transl Med (2007) 0.97
Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol (2006) 0.96
Simplified process for the production of anti-CD19-CAR-engineered T cells. Cytotherapy (2013) 0.95
The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol (2014) 0.95
Rational combinations of immunotherapeutics that target discrete pathways. J Immunother Cancer (2013) 0.95
In vivo imaging of immune cell trafficking in cancer. Eur J Nucl Med Mol Imaging (2010) 0.93
Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res (2011) 0.93
Selective modification of antigen-specific T cells by RNA electroporation. Hum Gene Ther (2008) 0.93
Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol (2007) 0.93
Impaired negative regulation of homeostatically proliferating T cells. Blood (2008) 0.92
The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol (2015) 0.91
Lessons from cancer immunoediting in cutaneous melanoma. Clin Dev Immunol (2012) 0.91
Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Des Devel Ther (2014) 0.91
Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells. J Immunother (2005) 0.88
Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells. PLoS One (2009) 0.88
KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity. J Clin Invest (2008) 0.88
Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes. J Immunother (2006) 0.87
Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival. Clin Immunol (2009) 0.86
Chronic alcohol consumption enhances myeloid-derived suppressor cells in B16BL6 melanoma-bearing mice. Cancer Immunol Immunother (2010) 0.86
A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy. J Immunol Res (2014) 0.85
Sentinel node lymphocytes: tumour reactive lymphocytes identified intraoperatively for the use in immunotherapy of colon cancer. Br J Cancer (2006) 0.85
Use of standard criteria for assessment of cancer vaccines. Lancet Oncol (2005) 0.84
Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunol Immunother (2008) 0.84
Molecular profiling of melanoma and the evolution of patient-specific therapy. Semin Oncol (2011) 0.84
Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials. Cytotherapy (2007) 0.84
Metastatic melanoma - a review of current and future drugs. Drugs Context (2012) 0.83
Novel immunotherapies. Cancer J (2009) 0.82
Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors. Mol Ther Methods Clin Dev (2014) 0.81
Engineered drug-resistant immunocompetent cells enhance tumor cell killing during a chemotherapy challenge. Biochem Biophys Res Commun (2009) 0.81
Value of large scale expansion of tumor infiltrating lymphocytes in a compartmentalised gas-permeable bag: interests for adoptive immunotherapy. J Transl Med (2011) 0.80
Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries. PLoS One (2010) 0.80
Identification of DRG-1 As a Melanoma-Associated Antigen Recognized by CD4+ Th1 Cells. PLoS One (2015) 0.80
Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist. J Invest Dermatol (2014) 0.80
Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers. Immunol Rev (2014) 0.80
Latest approved therapies for metastatic melanoma: what comes next? J Skin Cancer (2013) 0.80
Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies. J Biomed Biotechnol (2011) 0.80
Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells. J Transl Med (2014) 0.79
The clinical effects of dendritic cell vaccines combined with cytokine-induced killer cells intraperitoneal injected on patients with malignant ascites. Int J Clin Exp Med (2014) 0.79
Harnessing the Microbiome to Enhance Cancer Immunotherapy. J Immunol Res (2015) 0.79
Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer. J Transl Med (2011) 0.79
IL-15 signaling promotes adoptive effector T-cell survival and memory formation in irradiation-induced lymphopenia. Cell Biosci (2016) 0.79
Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8(+) T cells for adoptive immunotherapy of cancer and infections. Clin Exp Immunol (2016) 0.78
What's the place of immunotherapy in malignant mesothelioma treatments? Cell Adh Migr (2010) 0.78
Engineered T cells for cancer treatment. Cytotherapy (2013) 0.78
Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response. J Immunol Res (2016) 0.78
Antigen-presenting particle technology using inactivated surface-engineered viruses: induction of immune responses against infectious agents. Retrovirology (2007) 0.78
Chimeric antigen receptor-engineered T cells as oncolytic virus carriers. Mol Ther Oncolytics (2015) 0.77
Autocrine, not paracrine, interferon-gamma gene delivery enhances ex vivo antigen-specific cytotoxic T lymphocyte stimulation and killing. J Biomed Biotechnol (2010) 0.77
Generation and characterization of transgenic mice expressing a T-cell receptor specific for the tumour-associated antigen MDM2. Immunology (2008) 0.76
Induction/engineering, detection, selection, and expansion of clinical-grade human antigen-specific CD8 cytotoxic T cell clones for adoptive immunotherapy. J Biomed Biotechnol (2010) 0.76
Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells. Cancer Gene Ther (2008) 0.76
A study of T cell tolerance to the tumor-associated antigen MDM2: cytokines can restore antigen responsiveness, but not high avidity T cell function. PLoS One (2007) 0.76
Demethylation of cancer/testis antigens and CpG ODN stimulation enhance dendritic cell and cytotoxic T lymphocyte function in a mouse mammary model. Biomed Res Int (2013) 0.75
Tumor-Infiltrating CD8+ Lymphocytes Effect on Clinical Outcome of Muco-Cutaneous Melanoma. Indian J Dermatol (2015) 0.75
Characterization of human T lymphocytes engineered to express interleukin-15 and herpes simplex virus-thymidine kinase. J Surg Res (2013) 0.75
Targeting the dendritic cell: the key to immunotherapy in cancer? Clin Exp Immunol (2005) 0.75
Expanding the targets available to therapeutic antibodies via novel disease-specific markers. Int Rev Immunol (2011) 0.75
Manipulation of Innate and Adaptive Immunity through Cancer Vaccines. J Immunol Res (2017) 0.75
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A (1994) 8.92
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (1986) 8.07
Progress in human tumour immunology and immunotherapy. Nature (2001) 6.97
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A (1994) 6.93
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother (2001) 5.83
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother (2003) 5.59
Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med (1990) 5.27
Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer (2003) 4.99
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity (1999) 3.84
Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J Immunol (2001) 1.83
Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer (1998) 1.69
Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent. J Immunother (2003) 1.16
Gene therapy for cancer. JAMA (1992) 1.03
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (2014) 6.88
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 6.17
Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol (2009) 5.33
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol (2004) 4.73
PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J Clin Invest (2014) 3.54
Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther (2005) 3.49
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood (2013) 3.45
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther (2010) 3.29
Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol (2006) 3.15
Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood (2004) 3.05
Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother (2008) 2.57
Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clin Cancer Res (2012) 2.25
T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J Immunol (2004) 2.11
Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother (2004) 1.99
Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother (2005) 1.91
Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology (2009) 1.78
TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology (2012) 1.78
Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res (2011) 1.62
The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Sci Transl Med (2012) 1.61
Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother (2003) 1.55
Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer J (2010) 1.52
Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J Immunol (2013) 1.50
Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol (2006) 1.44
Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood (2012) 1.43
Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther (2008) 1.38
Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J Immunother (2010) 1.35
Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res (2010) 1.31
Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma. J Immunol (2004) 1.25
Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment. J Immunother (2012) 1.24
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. J Transl Med (2012) 1.23
Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy. J Immunother (2010) 1.21
Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells. Hum Gene Ther (2008) 1.17
Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes. J Immunother (2012) 1.09
Functional heterogeneity of vaccine-induced CD8(+) T cells. J Immunol (2002) 1.07
Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. J Immunol Methods (2009) 1.05
A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors. J Immunother (2010) 1.03
Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor. J Transl Med (2012) 0.98
Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. J Immunol (2013) 0.97
A T-cell receptor associated with naturally occurring human tumor immunity. Proc Natl Acad Sci U S A (2007) 0.96
Audiovestibular dysfunction associated with adoptive cell immunotherapy for melanoma. Otolaryngol Head Neck Surg (2012) 0.94
Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol Ther (2012) 0.94
Cancer immunotherapy. N Engl J Med (2008) 0.94
Bioreactors get personal. Oncoimmunology (2012) 0.90
Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma. J Immunother (2009) 0.88
IRF5 gene polymorphisms in melanoma. J Transl Med (2012) 0.86
Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy. Ann Surg Oncol (2009) 0.85
Evaluation of γ-retroviral vectors that mediate the inducible expression of IL-12 for clinical application. J Immunother (2012) 0.85
Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement. J Immunother (2011) 0.81
Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma. World J Surg Oncol (2012) 0.79
Thoracic metastasectomy for adoptive immunotherapy of melanoma: a single-institution experience. J Thorac Cardiovasc Surg (2010) 0.79
Proteasomal cleavage does not determine immunogenicity of gp100-derived peptides gp100 209-217 and gp100 209-217T210M. Cancer Immunol Immunother (2004) 0.78
A stimulating presentation. Nat Biotechnol (2002) 0.75
A major player "gets in the act". J Immunother (2012) 0.75